Prevalence, Transmission and Genetic Diversity of Pyrazinamide Resistance Among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Hunan, China
© 2024 Liu et al..
Background: China is a country with a burden of high rates of both TB and multidrug-resistant TB (MDR-TB). However, published data on pyrazinamide (PZA) resistance are still limited in Hunan province, China. This study investigated the prevalence, transmission, and genetic diversity of PZA resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Hunan province.
Methods: Drug susceptibility testing (DST) with the Bactec MGIT 960 PZA kit and pyrazinamidase (PZase) testing were conducted on all 298 MDR clinical isolates. Moreover, 24-locus MIRU-VNTR and DNA sequencing of pncA, rpsA, and panD genes were conducted on 180 PZA-resistant (PZA-R) isolates.
Results: The prevalence of PZA resistance among MDR-TB strains reached 60.4%. Newly diagnosed PZA-R TB patients and clustered isolates with identical pncA, rpsA, and panD mutations showed that transmission of PZA-R isolates played a significant role in the formation of PZA-R TB. Ninety-eight mutation patterns were observed in the pncA among 180 PZA-R isolates, and seventy-one (72.4%) were point mutations. Twenty-four of these mutations are new, including 2 base substitutions (V93G and T153S) and 22 nucleotide deletions or insertions. The W119C was found in PZA-S isolates, on the other hand, F94L and V155A mutations were found in both PZA resistant and susceptible isolates with positive PZase activity, indicating that they were not associated with PZA resistance. This is not entirely in line with the WHO catalogue. Ten novel rpsA mutations were found in 10 PZA-R isolates, which all combined with mutations in pncA. Thus, it is unpredictable whether these mutations in rpsA can impact PZA resistance. No panD mutation was found in all PZA-R isolates.
Conclusion: DNA sequencing of pncA and PZase activity testing have great potential in predicting PZA resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Infection and drug resistance - 17(2024) vom: 27., Seite 403-416 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Binbin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
China |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/IDR.S436161 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368175774 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368175774 | ||
| 003 | DE-627 | ||
| 005 | 20240210233331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240208s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/IDR.S436161 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM368175774 | ||
| 035 | |a (NLM)38328339 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Binbin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence, Transmission and Genetic Diversity of Pyrazinamide Resistance Among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Hunan, China |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 Liu et al. | ||
| 520 | |a Background: China is a country with a burden of high rates of both TB and multidrug-resistant TB (MDR-TB). However, published data on pyrazinamide (PZA) resistance are still limited in Hunan province, China. This study investigated the prevalence, transmission, and genetic diversity of PZA resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Hunan province | ||
| 520 | |a Methods: Drug susceptibility testing (DST) with the Bactec MGIT 960 PZA kit and pyrazinamidase (PZase) testing were conducted on all 298 MDR clinical isolates. Moreover, 24-locus MIRU-VNTR and DNA sequencing of pncA, rpsA, and panD genes were conducted on 180 PZA-resistant (PZA-R) isolates | ||
| 520 | |a Results: The prevalence of PZA resistance among MDR-TB strains reached 60.4%. Newly diagnosed PZA-R TB patients and clustered isolates with identical pncA, rpsA, and panD mutations showed that transmission of PZA-R isolates played a significant role in the formation of PZA-R TB. Ninety-eight mutation patterns were observed in the pncA among 180 PZA-R isolates, and seventy-one (72.4%) were point mutations. Twenty-four of these mutations are new, including 2 base substitutions (V93G and T153S) and 22 nucleotide deletions or insertions. The W119C was found in PZA-S isolates, on the other hand, F94L and V155A mutations were found in both PZA resistant and susceptible isolates with positive PZase activity, indicating that they were not associated with PZA resistance. This is not entirely in line with the WHO catalogue. Ten novel rpsA mutations were found in 10 PZA-R isolates, which all combined with mutations in pncA. Thus, it is unpredictable whether these mutations in rpsA can impact PZA resistance. No panD mutation was found in all PZA-R isolates | ||
| 520 | |a Conclusion: DNA sequencing of pncA and PZase activity testing have great potential in predicting PZA resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a China | |
| 650 | 4 | |a panD mutations | |
| 650 | 4 | |a pncA mutations | |
| 650 | 4 | |a pyrazinamide | |
| 650 | 4 | |a rpsA mutations | |
| 650 | 4 | |a transmission | |
| 650 | 4 | |a tuberculosis | |
| 700 | 1 | |a Su, Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Peilei |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Mi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wenbin |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Songlin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhenhua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaoping |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Jingwei |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Xiaojie |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jue |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Daofang |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Kanglin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Haican |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guilian |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Yunhong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection and drug resistance |d 2008 |g 17(2024) vom: 27., Seite 403-416 |w (DE-627)NLM209374322 |x 1178-6973 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2024 |g day:27 |g pages:403-416 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/IDR.S436161 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2024 |b 27 |h 403-416 | ||